Prime Editing for Isogenic iPSCs, PRINT, Universal In Vivo CAR T Editing, Biogen Q4 Results Disappoint; Andrea Choe

Episode 10 (February 23, 2024): Researchers from Francis Collins’ lab developed an efficient CRISPR prime editing protocol to generate isogenic-induced pluripotent stem cell (iPSC) lines carrying heterozygous or homozygous alleles for putatively causal single nucleotide variants. An RNA-based system known as PRINT can create and introduce site-specific, safe, and stable transgenes into the human genome. Astellas Pharma and Kelonia announced a nearly $800 million research collaboration and license agreement to develop innovative universal, off-the-shelf in vivo CAR T cell therapies. Fourth-quarter earnings and revenue fell short of expectations as Biogen worked to eliminate 1,000 jobs (11.5% of its workforce), among other cost-cutting actions, and restructured its pipeline after a slow start.


Plus, an interview with Andrea Choe, founder and chief executive officer at Holoclara.

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

Generation of Human Isogenic Induced Pluripotent Stem Cell Lines with CRISPR Prime Editing
The CRISPR Journal, February 14, 2024

Addressing Scientific Misconduct: An Interview with Elisabeth Bik
By Uduak Thomas, GEN Biotechnology, February 15, 2024

StockWatch: Biogen’s Q4 Results Disappoint Analysts
By Alex Philippidis, GEN Edge, February 18, 2024

Astellas and Kelonia Partner for $800M In Vivo CAR T Cell Therapies
By Jonathan D. Grinstein, PhD, GEN Edge, February 20, 2024

PRINT: Precise RNA-Mediated Insertion of Transgenes
GEN, February 21, 2024